FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"\n\n\n\nFSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Jan. 9, 2020\n\n\n\n- Management to Present at Biotech Showcase 2020 -\n TORONTO, Jan. 9, 2020 /CNW/ - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (\"FSD Pharma\" or the \"Company\") announced that its Class B Subordinate Voting Shares (the \"Shares\") will commence trading on the Nasdaq Capital Market under the symbol 'HUGE' today, January 9, 2020. The Company's Class B Subordinate Voting Shares will continue to trade on the Canadian Securities Exchange under the symbol 'HUGE'.\n\n \n \n\n \n\"The listing of our shares on the Nasdaq Capital Market is a momentous moment and represents a paradigm shift in the outlook of FSD Pharma,\" said Dr. Raza Bokhari. \"Doing so offers us an opportunity to expand awareness of the company's specialty pharmaceutical lead asset, a micronized formulation of palmitolylethonalamide (micro-PEA), which by targeting the CB2 receptor of the endocannabinoid system of the human body, may help address the opioid crisis by developing opioid-sparing, FDA-approved prescription drugs. A NASDAQ listing also elevates our corporate profile to institutional investors.\" \nDr. Bokhari will present at Biotech Showcase 2020 in San Francisco on Monday, January 13, 2020 at 3:30 pm PT where he will provide an overview of the Company, as well as recent strides made to transform FSD Pharma into a specialty pharmaceutical R&D company.   \nDr. Bokhari and members of the FSD Pharma leadership team will also meet with members of the global investment community while in San Francisco from January 13 to 15, 2020 on the sidelines of the JPMorgan 38th Annual Healthcare Conference. \nAbout FSD Pharma\nFSD Pharma is a specialty, biotech pharmaceutical R&D company focused on developing over time a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the centra...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B